stockrow
Saturday 7 November 2026
Export ACRS’s income statement to Excel — free account
Aclaris Therapeutics, Inc.
ACRS Healthcare Biotechnology
Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024.
- Revenue
- −55.1%
- EPS
- 0.00%
- Free cash flow
- −119.9%
Quarter to September 2026, against a year earlier
3.88
0.27
+7.48%
Follow ACRS
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
122.81 | 91.87 | 57.73 | 47.14 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(32.65) | (38.04) | (26.62) | (28.10) | |
P/B ratio |
4.71 | 6.06 | 3.36 | 3.58 | |
Price to Tangible BV |
4.92 | 6.42 | 3.53 | 3.84 | |
EV/Sales |
106.63 | 82.04 | 46.41 | 36.92 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.08) | (10.86) | (7.44) | (6.13) | |
EV/FCF |
(9.06) | (10.84) | (7.43) | (6.12) | |
Quick Ratio |
4.72 | 3.46 | 4.03 | 3.36 | |
Current Ratio |
5.09 | 3.46 | 4.03 | 3.36 | |
Net Debt/EBITDA |
5.38 | 3.79 | 4.77 | 4.01 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.04 | 0.04 | 0.04 | |
Operating CF/Net income |
1.30 | 0.92 | 0.92 | 0.66 | |
Capex/Depreciation |
(0.13) | (0.54) | (0.13) | (0.24) | |
Research and Development Expense of Revenue |
1,084.81% | 1,109.02% | 784.42% | 1,280.62% | |
Selling, General and Administrative Expense of Revenue |
407.70% | 371.27% | 337.83% | 430.58% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
203.85% | 164.03% | 160.22% | 225.95% | |
Graham Net Nets |
0.09 | 0.06 | 0.11 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.03%) | (10.96%) | (14.93%) | (17.61%) | |
Free Cash Flow Yield |
(9.58%) | (8.23%) | (10.82%) | (12.80%) | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.01 | |
Operating CF per Share |
(0.16) | (0.14) | (0.14) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.14) | (0.14) | (0.11) | |
Cash per Share |
0.76 | 0.64 | 0.82 | 0.74 | |
Shareholders Equity per Share |
1.12 | 0.87 | 1.12 | 0.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.12 | 0.87 | 1.12 | 0.84 | |
Free Cash Flow |
(24.09) | (19.90) | (18.16) | (13.15) | |
Working Capital |
99.01 | 69.52 | 82.86 | 67.67 | |
Capital Expenditures |
(0.01) | (0.06) | (0.01) | (0.02) | |
Net Current Asset Value |
73.87 | 42.65 | 55.16 | 38.94 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.04 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 3.20 | 2.53 | 8.96 | |
Average Payables |
9.13 | 12.16 | 10.54 | 8.92 | |
Average Assets |
195.85 | 184.42 | 198.41 | 190.39 | |
Average Common Equity |
143.45 | 128.16 | 143.86 | 129.32 |
Columns are period end dates · fundamentals updated 5 Nov 2026